SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?


To: 2MAR$ who wrote (26570)2/12/2003 10:47:03 AM
From: 2MAR$  Respond to of 57110
 
10:43 ET BGEN Biogen trades down on Avonex concerns (37.64 -0.94)
We are hearing that Sturza has learned that BGEN will send a "Dear Doctor" letter soon on new safety precautions for Avonex; firm says that similar warnings are not present in SRA/PFE's Rebif or CHIR/Schering AG's Betaseron labels, and they believe this is an additional negative for BGEN since it provides SRA's and PFE's salesforce with a compelling safety argument in Rebif's favor; thinks BGEN shares will trade down to $36 on this news, and reiterates Buy rating on SRA.